{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,26]],"date-time":"2026-07-26T03:50:58Z","timestamp":1785037858158,"version":"3.55.0"},"reference-count":22,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-017"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-037"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-012"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-029"},{"start":{"date-parts":[[2023,5,1]],"date-time":"2023-05-01T00:00:00Z","timestamp":1682899200000},"content-version":"stm-asf","delay-in-days":0,"URL":"https:\/\/doi.org\/10.15223\/policy-004"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","theclinics.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Clinics in Liver Disease"],"published-print":{"date-parts":[[2023,5]]},"DOI":"10.1016\/j.cld.2023.01.017","type":"journal-article","created":{"date-parts":[[2023,2,26]],"date-time":"2023-02-26T15:17:08Z","timestamp":1677424628000},"page":"353-362","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":14,"title":["Role of Liver Biopsy in Clinical Trials and Clinical Management of Nonalcoholic Fatty Liver Disease"],"prefix":"10.1016","volume":"27","author":[{"given":"Zachary D.","family":"Goodman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.cld.2023.01.017_bib1","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1002\/hep.20842","article-title":"Histopathology of pediatric nonalcoholic fatty liver disease","volume":"42","author":"Schwimmer","year":"2005","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2023.01.017_bib2","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1002\/ar.1091190103","article-title":"The structural and functional unit in the human liver (liver acinus)","volume":"119","author":"Rappaport","year":"1954","journal-title":"Anat Rec"},{"issue":"8222","key":"10.1016\/j.cld.2023.01.017_bib3","first-page":"707","article-title":"Alcoholic liver disease: morphological manifestations. Review by an international group","volume":"1","year":"1981","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2023.01.017_bib4","doi-asserted-by":"crossref","first-page":"1313","DOI":"10.1002\/hep.20701","article-title":"Design and validation of a histological scoring system for nonalcoholic fatty liver disease","volume":"41","author":"Kleiner","year":"2005","journal-title":"Hepatology"},{"issue":"10","key":"10.1016\/j.cld.2023.01.017_bib5","doi-asserted-by":"crossref","first-page":"e1912565","DOI":"10.1001\/jamanetworkopen.2019.12565","article-title":"Association of histologic disease activity with progression of nonalcoholic fatty liver disease","volume":"2","author":"Kleiner","year":"2019","journal-title":"JAMA Netw Open"},{"key":"10.1016\/j.cld.2023.01.017_bib6","doi-asserted-by":"crossref","first-page":"328","DOI":"10.1002\/hep.29367","article-title":"The diagnosis and management of nonalcoholic fatty liver disease: practice guidance from the American Association for the Study of Liver Diseases","volume":"67","author":"Chalasani","year":"2018","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2023.01.017_bib7","doi-asserted-by":"crossref","first-page":"2028","DOI":"10.1002\/hep.31599","article-title":"American association for the study of liver diseases NASH task force. NAFLD: reporting histologic findings in clinical practice","volume":"73","author":"Brunt","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2023.01.017_bib8","doi-asserted-by":"crossref","first-page":"1898","DOI":"10.1053\/j.gastro.2005.03.084","article-title":"Sampling variability of liver biopsy in nonalcoholic fatty liver disease","volume":"128","author":"Ratziu","year":"2005","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2023.01.017_bib9","doi-asserted-by":"crossref","first-page":"239","DOI":"10.1016\/S0168-8278(03)00191-0","article-title":"Impact of liver biopsy size on histological evaluation of chronic viral hepatitis: the smaller the sample, the milder the disease","volume":"39","author":"Colloredo","year":"2003","journal-title":"J\u00a0Hepatol"},{"key":"10.1016\/j.cld.2023.01.017_bib10","doi-asserted-by":"crossref","first-page":"1329","DOI":"10.1016\/j.cgh.2007.06.005","article-title":"Histopathologic variability between the right and left lobes of the liver in morbidly obese patients undergoing Roux-en-Y bypass","volume":"5","author":"Larson","year":"2007","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2023.01.017_bib11","doi-asserted-by":"crossref","first-page":"1017","DOI":"10.1002\/hep.22742","article-title":"American association for the study of liver diseases. Liver biopsy","volume":"49","author":"Rockey","year":"2009","journal-title":"Hepatology"},{"issue":"3","key":"10.1016\/j.cld.2023.01.017_bib12","doi-asserted-by":"crossref","first-page":"e564","DOI":"10.1016\/j.cgh.2021.05.059","article-title":"The placebo response in randomized trials in nonalcoholic steatohepatitis simply explained","volume":"20","author":"Rowe","year":"2022","journal-title":"Clin Gastroenterol Hepatol"},{"key":"10.1016\/j.cld.2023.01.017_bib13","doi-asserted-by":"crossref","first-page":"389","DOI":"10.1053\/j.gastro.2015.04.043","article-title":"Liver fibrosis, but no other histologic features, is associated with long-term outcomes of patients with nonalcoholic fatty liver disease","volume":"149","author":"Angulo","year":"2015","journal-title":"Gastroenterology"},{"key":"10.1016\/j.cld.2023.01.017_bib14","doi-asserted-by":"crossref","first-page":"1547","DOI":"10.1002\/hep.27368","article-title":"Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up","volume":"61","author":"Ekstedt","year":"2015","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2023.01.017_bib15","doi-asserted-by":"crossref","first-page":"1557","DOI":"10.1002\/hep.29085","article-title":"Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: systematic review and meta-analysis","volume":"65","author":"Dulai","year":"2017","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2023.01.017_bib16","unstructured":"U.S. Department of Health and Human Services, Food and drug administration, center for drug evaluation and research. Noncirrhotic nonalcoholic steatohepatitis with liver fibrosis: developing drugs for treatment draft guidance for industry, Available at: https:\/\/www.fda.gov\/media\/119044\/download, 2018. Accessed December 29, 2022."},{"key":"10.1016\/j.cld.2023.01.017_bib17","unstructured":"U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Nonalcoholic Steatohepatitis with Compensated Cirrhosis: Developing Drugs for Treatment: Guidance for Industry. 2019, Available at:https:\/\/www.fda.gov\/media\/127738\/download. Accessed December 29, 2022."},{"key":"10.1016\/j.cld.2023.01.017_bib18","doi-asserted-by":"crossref","first-page":"2023","DOI":"10.1002\/hep.31687","article-title":"Nonalcoholic steatohepatitis: current thinking from the division of hepatology and nutrition at the food and drug administration","volume":"73","author":"Anania","year":"2021","journal-title":"Hepatology"},{"key":"10.1016\/j.cld.2023.01.017_bib19","doi-asserted-by":"crossref","first-page":"956","DOI":"10.1016\/S0140-6736(14)61933-4","article-title":"Farnesoid X nuclear receptor ligand obeticholic acid for non-cirrhotic, non-alcoholic steatohepatitis (FLINT): a multicentre, randomised, placebo-controlled trial","volume":"385","author":"Neuschwander-Tetri","year":"2015","journal-title":"Lancet"},{"key":"10.1016\/j.cld.2023.01.017_bib20","doi-asserted-by":"crossref","first-page":"1675","DOI":"10.1056\/NEJMoa0907929","article-title":"Pioglitazone, vitamin E, or placebo for nonalcoholic steatohepatitis","volume":"362","author":"Sanyal","year":"2010","journal-title":"N\u00a0Engl J Med"},{"issue":"1","key":"10.1016\/j.cld.2023.01.017_bib21","doi-asserted-by":"crossref","first-page":"344","DOI":"10.1002\/hep.24376","article-title":"Endpoints and clinical trial design for nonalcoholic steatohepatitis","volume":"54","author":"Sanyal","year":"2011","journal-title":"Hepatology"},{"issue":"5","key":"10.1016\/j.cld.2023.01.017_bib22","doi-asserted-by":"crossref","first-page":"1841","DOI":"10.1002\/hep.30672","article-title":"Liver forum case definitions working group. defining improvement in nonalcoholic steatohepatitis for treatment trial endpoints: recommendations from the liver forum","volume":"70","author":"Cheung","year":"2019","journal-title":"Hepatology"}],"container-title":["Clinics in Liver Disease"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108932612300017X?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S108932612300017X?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,10,21]],"date-time":"2025-10-21T18:01:24Z","timestamp":1761069684000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S108932612300017X"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2023,5]]},"references-count":22,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2023,5]]}},"alternative-id":["S108932612300017X"],"URL":"https:\/\/doi.org\/10.1016\/j.cld.2023.01.017","relation":{},"ISSN":["1089-3261"],"issn-type":[{"value":"1089-3261","type":"print"}],"subject":[],"published":{"date-parts":[[2023,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Role of Liver Biopsy in Clinical Trials and Clinical Management of Nonalcoholic Fatty Liver Disease","name":"articletitle","label":"Article Title"},{"value":"Clinics in Liver Disease","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.cld.2023.01.017","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2023 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}